Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993655 · ClinicalTrials.gov registry record · Phase 2
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
A Phase 2 study, sponsored by Canadian Cancer Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
NCT00993655: Completed Phase 2 study, sponsored by Canadian Cancer Trials Group.
NCT00993655 is a Phase 2 study that has completed, run by Canadian Cancer Trials Group. The registered enrollment target is 275 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00993655, a Phase 2 study, has completed, sponsored by Canadian Cancer Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube cancer. PURPOSE: This randomized phase II trial is comparing the side effects of three combination chemotherapy regimens and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
Primary Outcome
It is defined as proportion of patients who had progressed at or before 9 months after randomization, i.e., the time from the randomization to the date when the first observation of disease progression (earliest of the date when the first CA 125 meets progression definition and the date of first objective relapse or progression, defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurabl
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2010-03-03 |
| Est. Completion | 2016-07-11 |
| Phase | Phase 2 |
What the finished NCT00993655 record still lists
NCT00993655 is an interventional study that assigns participants to a tested intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00993655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00993655 about?
NCT00993655 is a clinical study titled "Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may k...
What is the current status of trial NCT00993655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2010-03-03. Estimated completion is 2016-07-11.
What interventions are being tested in trial NCT00993655?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00993655?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00993655's enrollment target sits among peer trials
275 203rd of 2000 higher than 1,798 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI